| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
AGI-5198 (also know as IDH-C35; IDHC35; AGI-5198; AGI 5198) is a novel, highly potent and selective inhibitor of IDH1 (isocitrate dehydrogenase 1) R132H/R132C mutants with potential anticancer activity. It inhibits IDH1 R132H/R132C with IC50 of 0.07 μM/0.16 μM, respectively. AGI-5198 demonstrates significant in vivo antitumor efficacy in IDH1 mutant glioma xenografts.
| ln Vitro |
The amount of R-2HG in TS603 glioma cell pellets was measured, and the results showed that AGI-5198 inhibited the mutant IDH1 enzyme in a dose-dependent manner. In two patient-derived glioma cell lines (TS676 and TS516) that express exclusively wild-type IDH1 alleles, AGI-5198 has no effect on colony formation [1]. When exposed to ionizing radiation (IR), cancer cells heterozygous for the IDH1 (R132H) mutation show reduced IDH-mediated NADPH generation and consequently increased amounts of reactive oxygen species, or DNA, compared to IDH1 wild-type cells. Double-strand breaks and cell death are also observed. These effects are reversed by AGI-5198, an IDH1 (R132H) inhibitor [2].
|
||
|---|---|---|---|
| ln Vivo |
In human glioma xenografts, AGI-5198 (450 mg/kg, po) inhibits tumor growth by 50% to 60%. Mice treated with AGI-5198 had tumors that stained less strongly with anti-Ki-67 antibodies. Glioma xenografts of the IDH1 wild-type grow unaffected by AGI-5198 [1].
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 R132H inhibitor
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide has been reported in Aspergillus flavipes with data available. |
| Molecular Formula |
C27H31FN4O2
|
|
|---|---|---|
| Molecular Weight |
462.56
|
|
| Exact Mass |
462.243
|
|
| CAS # |
1355326-35-0
|
|
| Related CAS # |
|
|
| PubChem CID |
56645356
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.2±0.1 g/cm3
|
|
| Boiling Point |
707.6±60.0 °C at 760 mmHg
|
|
| Flash Point |
381.7±32.9 °C
|
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
|
| Index of Refraction |
1.613
|
|
| LogP |
4.05
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
34
|
|
| Complexity |
686
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
FNYGWXSATBUBER-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10,13-17,22,26H,3-5,11-12,18H2,1-2H3,(H,30,34)
|
|
| Chemical Name |
N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide
|
|
| Synonyms |
IDH C35; AGI5198; IDH-C35; IDHC35; AGI-5198; AGI 5198;
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (4.50 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% methylcellulose+0.2% Tween 80: 30mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1619 mL | 10.8094 mL | 21.6188 mL | |
| 5 mM | 0.4324 mL | 2.1619 mL | 4.3238 mL | |
| 10 mM | 0.2162 mL | 1.0809 mL | 2.1619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
